Determined.
Focused on the development of novel and highly efficacious drugs for the treatment of inflammatory diseases
About us
Founded in December 2017, Temisis Therapeutics (“Temisis”) is a pre-clinical biotechnology company focused on the development of novel and highly efficacious compounds for the treatment of inflammatory diseases with high unmet needs.
In ongoing pre-clinical trials, Temisis’ proprietary programs, including TEM-1657, have shown significant efficacy and a best-in-class safety profile to treat psoriasis, with none of the common side effects associated with existing topical and oral treatments.
Technology
Our proprietary and novel small-molecule pre-clinical programs, including TEM1657, have showed great efficacy, orally and topically, to remit psoriasis symptoms but without the common side effects associated with existing treatments.
1
Rapid efficacy
Inflammatory symptoms are rapidly reduced after the first application of our lead compounds, including TEM1657, in line with existing topical and oral treatments
2
Complete remission of psoriasis symptoms
No erythema – Regulated desquamation – Normal skin thickness
Greater efficacy than existing oral treatments (Apremilast)
Similar efficacy than existing topical corticosteroid treatments
3
Best-in class safety profile
No skin thinning (unlike corticosteroids), no observed side effect on animals in toxicity tests.
No common side effects associated with existing topical and oral treatments.
![temisis-logo-s](https://www.temisis.com/wp-content/uploads/2018/10/temisis-logo-s.png)
19 av de la Forêt de Haye,
54500 Vandœuvre-lès-Nancy
France
Tel.: +33 (0) 383 940 342
contact@temisis.com
www.temisis.com
![icon-contact icon-contact](https://www.temisis.com/wp-content/uploads/2018/10/icon-contact.png)